Eli Lilly Stock (LLY): $320 Price Target From BMO Capital

By Amit Chowdhry ● Dec 19, 2021
  • The shares of Eli Lilly And Co (NYSE: LLY) have received a price target of $320 from BMO Capital. These are the details.

The shares of Eli Lilly And Co (NYSE: LLY) have received a price target of $320 from BMO Capital. And BMO Capital analyst Evan Seigerman increased the price target from $311 while maintaining an “Outperform” rating on the company shares.

Seigerman made the adjustment following the company’s Analyst Day event and after the company increased their guidance. Seigerman is impressed by the company’s longer-term margin leverage of the business and the deep R&D pipeline.

Plus Seigerman noted that the diabetes operations will lead to durable and sustained growth. And Lilly’s pipeline strategy is starting to bear fruit with a near-term submission of its AD drug donanemab while the company’s oncology franchise will help support its profitability in the years to come.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.